Spravato Nasal spray solution
Esketamine
28 mg/Nasal Spray device
Janssen Cilag International N.V
| Pack size | 1 Kit [1 Nasal Spray Device (28 mg)] |
|---|---|
| Dispensing mode | CD |
| Source | BELGIUM |
| Agent | MODERN PHARMACEUTICAL COMPANY |
| Retail Price | 1238.50 AED |
Available as:
Indications
Spravato Nasal spray solution is used for:
This drug is indicated in conjunction with an oral antidepressant for the treatment of treatment-resistant depression (TRD) in adults [FDA label].
Note: Esketamine is not approved as an anesthetic agent. The safety and effectiveness of esketamine as an anesthetic agent have not been established to this date [FDA label].
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Esketamine :
Mechanism of Action
Esketamine, the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. The exact mechanism by which esketamine acts as an antidepressant is unknown. The primary circulating metabolite of esketamine (_noresketamine_) shows activity at the same receptor with a weaker affinity [FDA label].
Note
Spravato 28 mg/Nasal Spray device Nasal spray solution manufactured by Janssen Cilag International N.V . Its generic name is Esketamine. Spravato is availble in United Arab Emirates.
Farmaco UAE drug index information on Spravato Nasal spray solution is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.